Company Filing History:

6 out of 1,829

Schering Corporation

patents

6 out of 52

Pharmacopeia Drug Discovery, Inc.

patents

4 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2005-2014

Loading Chart...

12 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 8829036 - Heterocyclic aspartyl protease inhibitors (2014-09-09),

2. 8778980 - Heterocyclic aspartyl protease inhibitors (2014-07-15),

3. 8691833 - Heterocyclic aspartyl protease inhibitors (2014-04-08),

4. 8691831 - Heterocyclic aspartyl protease inhibitors (2014-04-08),

5. 8242112 - Heterocyclic aspartyl protease inhibitors (2012-08-14),

6. 8178513 - Heterocyclic aspartyl protease inhibitors (2012-05-15),

7. 7763609 - Heterocyclic aspartyl protease inhibitors (2010-07-27),

8. 7700603 - Heterocyclic aspartyl protease inhibitors (2010-04-20),

9. 7592348 - Heterocyclic aspartyl protease inhibitors (2009-09-22),

10. 7511146 - 2-substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders (2009-03-31),

11. 7034056 - Aryl and biaryl compounds having MCH modulatory activity (2006-04-25),

12. 6887889 - Aryl and biaryl piperdines with MCH modulatory activity (2005-05-03),

Title: Rachael Catherine Hunter: Innovator in Pharmaceutical Research

Introduction

Rachael Catherine Hunter, located in Princeton, NJ, is a distinguished inventor with a remarkable portfolio of 12 patents. Her innovative work prominently focuses on the development of pharmaceutical compounds aimed at treating various diseases. Rachael's contributions have significantly advanced the field, particularly through her latest patents.

Latest Patents

Rachael's most recent inventions pertain to heterocyclic aspartyl protease inhibitors. These patents disclose compounds characterized by a specific formula, including their stereoisomers, tautomers, and pharmaceutically acceptable salts or solvates. She has categorized methods for inhibiting aspartyl protease, which are particularly geared towards treating cardiovascular diseases, cognitive and neurodegenerative disorders. Furthermore, Rachael's research includes methods aimed at inhibiting the Human Immunodeficiency Virus, plasmepins, cathepsin D, and protozoal enzymes. Notably, her work also explores treating cognitive and neurodegenerative diseases with her compounds in combination with cholinesterase inhibitors or muscarinic agonists or antagonists.

Career Highlights

Rachael has garnered vast experience throughout her career by working with esteemed organizations such as Schering Corporation and Pharmacopeia Drug Discovery, Inc. Her extensive research pursuits have enabled her to hold a significant position in the pharmaceutical innovation landscape.

Collaborations

Throughout her career, Rachael has had the opportunity to collaborate closely with talented individuals, including Tao Guo and William J Greenlee. Their joint efforts have contributed to the advancement of research and development in her field.

Conclusion

Rachael Catherine Hunter's dedication to innovation in pharmaceutical research is evident through her numerous patents and impactful collaborations. Her work continues to pave the way for advancements in treatments for critical health conditions, demonstrating the profound impact of her contributions to the scientific community.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.